All In Biotech

Drug Trial Radar · NCT06308406

A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

Last checked: Nov 20, 2026Latest source record: Apr 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

54

Planned (sponsor's estimate)

Start

Mar 15, 2024

Primary completion

Oct 2025

Study completion Oct 2025

Sponsor

Sponsor type
Industry
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, open-label Phase Ib/II clinical trial to observe and evaluate the safety, tolerability and pharmacokinetics of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer mechanical characterization and preliminary evaluation of the efficacy of HRS-1167 in combination with bevacizumab in patients with recurrent ovarian cancer.

Conditions

  • Recurrent Ovarian Cancer

Interventions

  • Bevacizumab; HRS-1167Drug

    Bevacizumab: injection, 100mg(4mL), intravenous infusion HRS-1167: Tablets, 25mg/tablet, oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of subjects with dose-limiting toxicity (DLT)Time frame: From first dose of study treatment until the end of Cycle 1(up to 21 days)
  2. Determination of Recommended Phase II dose (RP2D)Time frame: From first dose of study treatment until the end of Cycle 1(up to 21 days)

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of University of Science and Technology of China

    Hefei, Anhui, China · Not yet recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China · Not yet recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Not yet recruiting

  • Shandong First Medical University Affiliated Cancer Hospital

    Jinan, Shangdong, China · Not yet recruiting

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.